Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-07-05 09:51 GMT | Update On 2025-07-05 09:51 GMT

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended granting permission to initiate a Phase III clinical trial for the new drug Gefapixant Tablets 45 mg, based on the bioequivalence (BE) study submitted by Sun Pharma Laboratories.

This recommendation was made following a detailed review of the BE study report presented during the SEC Pulmonary meeting held on 28th May 2025.

Gefapixant is a first-in-class, non-narcotic, selective P2X3 receptor antagonist being developed for the treatment of refractory or unexplained chronic cough—a condition estimated to affect 5–10% of adults globally, defined as a cough lasting more than eight weeks.

The drug works by inhibiting ATP binding to P2X3 receptors, thereby reducing excessive activation of vagal C fibers by extracellular ATP, which dampens the cough reflex.

Following deliberation, the SEC concluded that the results of the BE study supported further clinical development and therefore recommended the initiation of the Phase III clinical trial. The committee has directed the company to submit the results of the Phase III trial to CDSCO for further evaluation.

Also Read: Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate FDC

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

Similar News

Govt Panel Makes This Approval Mandatory For New Drug Licenses

CDSCO Panel Asks Glenmark To Justify BE Waiver for FDC Inhalation Suspension With Scientific Evidence

Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic Dermatitis

Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma

High-Alcohol Medicinal Preparations to Come Under Schedule H1: Govt Panel Approves Rule Change

Delhi HC Flags Off-Label Use of Diabetes Drugs for Weight Loss, Seeks CDSCO Report

Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate FDC